Table 5.
Comparison of EC50 values (µM) of cell kill of human breast, prostate, bladder and pancreatic cancer cell lines versus conventional agents. Cells were exposed to drugs, and the CFDA-AM assay used as a marker of cell proliferation. Data represent n = 6–8 from three separate experiments.
| Cell Line | DT320 |
Conventional Agent |
||
|---|---|---|---|---|
| SISgel | Monolayer | SISgel | Monolayer | |
| MDA-MB-435 (breast) | 8.7 ± 1.1 | 78.1 ± 7.1 | 47.8 ± 4.0 (D) | 45.4 ± 1.9 (D) |
| PC-3 (prostate) | 19.7 ± 2.0 | 41.5 ± 4.1 | 102.2 ± 7.0 (D) | 104.1 ± 6.1 (D) |
| J82 (bladder) | 30.9 ± 4.8 | 71.2 ± 8.1 | >300 (C) | 102.3 ± 10.2 (C) |
| Capan-1 (pancreatic) | 22.9 ± 4.8 | 80.1 ± 10.2 | 83.1 ± 10.7 (G) | 78.2 ± 9.8 (G) |
D, doxorubicin; G, gemcitabine; C, cisplatin.